BMS scraps cell therapy manufacturing agreement, Cellares to restructure
Bristol Myers Squibb has terminated its partnership with Cellares after evaluating the manufacturer's Cell Shuttle platform. The decision will lead to a corporate reorganization at Cellares. The move reflects a shift in BMS's external manufacturing strategy for cell therapies.
The termination of Bristol Myers Squibb’s partnership with Cellares marks a notable adjustment in how major pharmaceutical companies approach the production of advanced cell therapies. BMS had been evaluating Cellares’ automated Cell Shuttle platform as part of its external manufacturing network, but after that assessment, chose to end the agreement. For Cellares, the loss of a key client necessitates a corporate restructuring, signaling the fragility of contract manufacturing relationships in a field where technology validation and scale-up costs are high. This development underscores the broader volatility in cell therapy manufacturing, where partnerships are often reassessed as companies refine their internal capabilities and prioritize flexibility over long-term external commitments.
This shift could affect patients awaiting cell therapies if manufacturing bottlenecks delay product availability, though BMS’s move may also streamline its supply chain. Smaller manufacturers like Cellares may face financial strain, potentially reducing innovation and competition. Ultimately, the impact depends on how quickly alternative partnerships or internal production fill the gap, influencing drug costs and access for chronic and cancer patients.